Pharma Two B to Present Additional Positive Results from P2B001 Phase 3 Trial at 2023 American Academy of Neurology Annual Meeting Results showed P2B001, a once-daily fixed-dose combination of low dose pramipexole and low dose rasagiline, showed comparable efficacy to marketed optimally titrated pramipexole, with significantly...

Longboard Pharmaceuticals to Present Phase 1 Data for LP352 at the American Academy of Neurology Annual Meeting Two poster presentations highlight Phase 1 data for LP352 in healthy volunteers SAN DIEGO, April 01, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage...

Data at AAN Demonstrate Biogen’s Leadership and Commitment to Innovation in MS Updated results support lower risk of PML with extended interval dosing (EID; approximately every six weeks) for TYSABRI® (natalizumab) in patients in a real-world setting New interim data further...

MDA, AAN and ABF Award Clinical Research Training Fellowship for Muscular Dystrophy Chicago, IL, July 14, 2017 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA), together with the American Academy of Neurology (AAN) and the American Brain Foundation (ABF), is pleased to...